Leukemic stem cell persistence in chronic myeloid leukemia patients in deep molecular response induced by tyrosine kinase inhibitors and the impact of therapy discontinuation

During the last decade, the use of tyrosine kinase inhibitor (TKI) therapy has modified the natural history of chronic myeloid leukemia (CML) allowing an increase of the overall and disease-free survival, especially in patients in whom molecular residual disease becomes undetectable. However, it has...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Oncotarget
Glavni autori: Chomel, Jean Claude, Bonnet, Marie Laure, Sorel, Nathalie, Sloma, Ivan, Bennaceur-Griscelli, Annelise, Rea, Delphine, Legros, Laurence, Marfaing-Koka, Anne, Bourhis, Jean-Henri, Ame, Shanti, Guerci-Bresler, Agnès, Rousselot, Philippe, Turhan, Ali G.
Format: Artigo
Jezik:Inglês
Izdano: Impact Journals LLC 2016
Teme:
Research Paper
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5085229/
https://ncbi.nlm.nih.gov/pubmed/27167108
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.9182
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items